| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT07489287 GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer |
Recruitment opened |
| 2026-06-02 | NCT05231122 Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for… |
date change Primary completion pushed: 2026-12-30 -> 2027-03-15 |
| 2026-06-02 | NCT05231122 Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for… |
date change Completion pushed: 2026-12-30 -> 2027-03-15 |
| 2026-06-02 | NCT07182240 Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs… |
date change Primary completion pushed: 2026-12-22 -> 2027-06-22 |
| 2026-06-02 | NCT07182240 Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs… |
date change Completion pushed: 2026-12-22 -> 2027-06-22 |
| 2026-05-23 | NCT07107139 Influence of Authorized Smokeless Tobacco Product Modified Risk Claims II: Laboratory… |
date change Primary completion pushed: 2027-03-01 -> 2027-05-01 |
| 2026-05-23 | NCT07107139 Influence of Authorized Smokeless Tobacco Product Modified Risk Claims II: Laboratory… |
date change Completion pushed: 2027-03-01 -> 2027-05-01 |
| 2026-05-21 | NCT06863402 Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse… |
date change Primary completion pushed: 2029-04-01 -> 2029-06-01 |
| 2026-05-21 | NCT06863402 Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse… |
date change Completion pushed: 2030-04-01 -> 2030-06-01 |
| 2026-05-16 | NCT06305598 Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for… |
date change Primary completion pushed: 2026-12-15 -> 2029-12-15 |
| 2026-05-16 | NCT06305598 Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for… |
date change Completion pushed: 2027-12-15 -> 2029-12-15 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06733350 | Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men… | Localized Prostate Carcinoma | Recruiting |
| Phase 3 | |||
| NCT06563388 | Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic… | Oligometastasis | Recruiting |
| Phase 2 | |||
| NCT04682158 | Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma | Esophageal Adenocarcinoma | Recruiting |
| NCT06627751 | Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory… | Extramedullary Disease in Multiple Myeloma | Recruiting |
| NCT06995508 | Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing… | Cancer-Associated Anorexia | Recruiting |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab… | Fallopian Tube Carcinosarcoma | Recruiting |
| NCT06821997 | NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal… | Borderline Resectable Pancreatic Ductal Adenocarcinoma | Recruiting |
| NCT06434064 | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With… | Anatomic Stage III Breast Cancer AJCC v8 | Recruiting |
| NCT04068649 | Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients… | Metastatic Malignant Neoplasm | Recruiting |
| NCT07017829 | GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11… | Advanced Lung Non-Small Cell Carcinoma | Recruiting |
| NCT06733363 | A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and… | Non-Muscle Invasive Bladder Carcinoma | Recruiting |
| NCT04348747 | Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain… | Anatomic Stage IV Breast Cancer AJCC v8 | Recruiting |
| NCT04067830 | Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients… | Stage I Lung Cancer AJCC v8 | Recruiting |
| NCT06863402 | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse… | Richter Syndrome | Recruiting |
| NCT06202066 | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients… | Digestive System Neuroendocrine Neoplasm | Recruiting |
| NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for… | Ovarian Clear Cell Adenocarcinoma | Recruiting |
| NCT06827054 | Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring… | Hematopoietic and Lymphatic System Neoplasm | Not Yet Recruiting |
| NCT06943664 | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory… | Lung Non-Small Cell Carcinoma | Not Yet Recruiting |
| NCT02455557 | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed… | Glioblastoma | Active, Not Recruiting |
| NCT04876248 | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients… | Plasma Cell Myeloma | Active, Not Recruiting |
| NCT07543172 | CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non… | Advanced Lung Non-Small Cell Carcinoma | Not Yet Recruiting |
| NCT04032418 | Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small… | Lung Non-Small Cell Carcinoma | Active, Not Recruiting |
| NCT03899987 | Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With… | Prostate Adenocarcinoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT03965234 | Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or… | Metastatic Bone Sarcoma | Recruiting |
| NCT06306638 | Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients… | Malignant Solid Neoplasm | Recruiting |